Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading higher by 9.25% to $24.80 Thursday morning after the company announced it raised $235 million in net proceeds.
What Happened: Summit Therapeutics announced that it raised approximately $235 million by selling 10.35 million shares at $22.70 per share, matching the closing price on September 11.
The capital raise, completed without bankers' fees, involved investments from both biotech institutional investors and company insiders, including key executives and Board members. Insiders, led by figures like Robert W. Duggan and Dr. Maky Zanganeh, contributed $79 million, while institutional investors raised the remaining $156 million.
The funds will be used to advance clinical development of ivonescimab for lung cancer and other cancers, as well as for general corporate purposes.
週四上午，Summit Therapeutics Inc（納斯達克股票代碼：SMMT）股價上漲9.25％，至24.80美元，此前該公司宣佈籌集了2.35億美元的淨收益。
發生了什麼：Summit Therapeutics宣佈，它以每股22.70美元的價格出售了103.5萬股股票，籌集了約2.35億美元，與9月11日的收盤價持平。
此次融資是在不收取銀行費用的情況下完成的，涉及生物技術機構投資者和公司內部人士（包括主要高管和董事會成員）的投資。由羅伯特·杜根和馬基·贊加內博士等人物領導的內部人士出資7900萬美元，而機構投資者則籌集了剩餘的1.56億美元。
這筆資金將用於推進用於肺癌和其他癌症以及一般公司用途的依文西單抗的臨床開發。
